Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Polls

Editorial Advisory Board

Partners

Subscribe

Kaitlyn Bader is the assistant managing editor of 

 and joined the MJH Life Sciences team in June 2022. She attended Otterbein University in Westerville, Ohio, and earned a Bachelor of Arts degree in literary studies with minors in creative writing and film studies. Prior to health care news, Kaitlyn worked in industrial marketing. She enjoys cooking, reading, and tending to her house plants.

Articles

In case you missed it, we had news about benzene in benzoyl peroxide acne products tested at room temperature, the FDA's approved sNDA for 3 tubes of aminolevulinic acid hydrochloride, phase 2b trial data of zasocitinib, and more.

The Weekly Roundup: October 7-11

The novel drug demonstrated tolerability for AK treatment when applied to a field of 100 cm2 of the face or scalp.

Tirbanibulin Demonstrates Efficacy for Actinic Keratosis in Larger Field Treatment

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Significant reductions in itch scores and improved assessments of PN severity and quality of life were observed throughout the study.

Safe and Effective: Upadacitinib Shows Promise in PN Treatment

A recent review found clinical trials for HS lack diversity, limiting understanding of treatment efficacy for SOC populations.

Disparities in Hidradenitis Suppurativa: A Closer Look at Skin of Color Populations

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

clinical

Clinical

A biologic from Germany offers a new treatment option for a number of dermatologic conditions.

FDA Approves Adalimumab-aacf for Plaque Psoriasis, Hidradenitis Suppurativa and Other Conditions

At the 2022 Fall Clinical Dermatology Conference in Las Vegas, Aaron S. Farberg, MD, shares data on the treatment of plaque psoriasis using tildrakizumab-asmn.

Consistent Efficacy With a Durable Safety Profile Through 5 Years and a Growing Body of Real-World Evidence

The company announced the results from its long-term extension study, highlighting improved efficacy outcomes, quality of life, and tolerability data. 

Dermavant Announces Phase 3 PSOARING 3 Tapinarof Cream Data at AAD 2022

The New England Journal of Medicine has published the clinical trial data from the PSOARING 1 and PSOARING 2 studies on tapinarof treatment for plaque psoriasis. 

Phase 3 Tapinarof Data Released

The pro-inflammatory transcription factor is critical for the expression of IL-23, which is known to play a role in psoriasis.

C-Jun Protein Linked to Psoriasis

Comparison of Systemic Therapies for Plaque Psoriasis

Videos

I'm sorry, it seems there is no article provided for me to summarize and extract key takeaways from. Could you please provide the text of the article

An expert on plaque psoriasis provides an overview of systemic therapy options and provides clinical insights on patient monitoring practices and best courses of action when treatment response isn’t sustained.

Video Series

Case 2: Management of a 58-Year-Old Patient with Location-Specific Plaque Psoriasis, Psoriatic Arthritis, Type 2 Diabetes, and Obesity

I'm sorry, but it seems there is no article provided for me to summarize and extract key takeaways from. Could you please provide the text of the article

E. James Song, MD, FAAD, presents a case of a 58-year-old patient with location-specific mild-to-moderate plaque psoriasis.

Optimizing Therapy Escalation: Navigating Insurance Barriers and Step Therapy for Patients with Plaque Psoriasis

A dermatologist provides clinical insights on navigating dose escalation and insurance barriers for patients receiving treatment for plaque psoriasis.

Case 1: Evaluating Treatment History and Future Management Strategies for a Patient with Mild-to-Moderate Plaque Psoriasis

Continuing discussion on a case of a 45-year-old patient with plaque psoriasis, E. James Song, MD, FAAD, discusses management strategies for patients with mild-to-moderate plaque psoriasis.

Role of PDE-4 in the Management of Plaque Psoriasis

Focusing on treatment paradigms in plaque psoriasis, E. James Song, MD, FAAD, provides insights on phosphodiesterase inhibitors 4 (PDE-4) and their role in the therapeutic landscape.

Management of Plaque Psoriasis in a 45-year-old Woman via Telemedicine

E. James Song, MD, FAAD, presents the case of a 45-year-old woman with plaque psoriasis who lives in a rural area, introducing a discussion on clinical telemedicine practices.

Morphological Differences of Plaque Psoriasis vs Eczema Skin Conditions

A dermatologist describes the factors that differentiate plaque psoriasis from other dermatological conditions and how they inform treatment approaches.

Evolution of Plaque Psoriasis Understanding, Pathophysiology, and Treatment Options

E. James Song, MD, FAAD, provides detailed insights on how our understanding of plaque psoriasis has evolved and the ways that has impacted treatment options and decisions.

Melinda Gooderham, MD, MSc, FRCPC, study investigator of the DERMIS-1 and DERMIS-2 phase 3 trials of roflumilast cream 0.3% (ZORYVE; Arcutis Biotherapeutics) for plaque psoriasis, discussed the value of roflumilast cream for patients with psoriasis. Data from each pivotal phase 3 trial was recently published in the 

Journal of the American Medical Association

Results showed that in both studies, significantly more participants treated with roflumilast cream reached Investigator's Global Assessment (IGA) success at week 8 compared to the control group of vehicle-treated participants (DERMIS-1: 42.4% vs 6.1%; DERMIS-2: 37.5% vs. 6.9%, P<0.001 for both). Roflumilast cream was successful in intertriginous areas, where two areas of skin may rub together, with significantly more roflumilast-treated participants achieving intertriginous success at week 8 than vehicle-treated patients. Gooderham explained how roflumilast cream will help increase the quality of life for patients with psoriasis.

Hello, I'm Melinda Gooderham, dermatologist and clinical researcher from Peterborough, Ontario, Canada. I was an investigator, not only in the DERMIS-1 and 2 trials, I've been an investigator in this program since phase one. So, I've had quite a bit of experience using roflumilast topically, but as an investigator in DERMIS-1 and DERMIS-2, we were able to treat a larger group of patients. The approval for the medication was received by the FDA in July of this year. And then recently this week, we had a publication in the 

. So that was quite an honor to be published in that journal. But my general thoughts about how this product will impact patients is that I really feel it will simplify the life of psoriasis patients which can often be very complicated. They have itchy, visible plaques that they're trying to hide, and they're using multiple different products to treat them. With roflumilast, it will bring some simplicity in that it is one product that is used once a day in all areas, so you can use it in the sensitive areas, you can use it in the difficult to treat areas like the elbows and the knees. And it was very well tolerated. So, unlike some other PD-4 inhibitors that we've used topically, other nonsteroidal agents that we use off label for psoriasis topically, can cause some burning and stinging, which will lead to patients not being very adherent to topical application. But we did not see that in any of the trials that are done with roflumilast. It was very well tolerated by patients. It's a very nice vehicle that uses very cosmetically acceptable ingredients to make it non greasy. So, they can put it on once a day, it doesn't get on their clothes, they're happy to use it because it makes the skin feel good and adds that simplicity to their life.

It also can simplify the dermatologist's life because instead of prescribing a number of different topicals for sensitive areas and hard-to-treat areas and then hoping that the patients don't mix them up and use the wrong product in the wrong place leading to some adverse effects, we can feel confident that we can give one product that will work in other areas only by writing one prescription one refill. And also, without the calls to the clinic with issues with burning, stinging or not being able to tolerate or it being too greasy and getting on clothes, sheets, that sort of thing. I guess overall the simplicity for the patient, the once a day, one product, all areas, simplicity from the prescriber to give one product that they know can treat all of their psoriasis, and with that tolerability that will ultimately improve the patient's quality of life, which is what we're trying to do in the first place as dermatologists.

One other thing that we don't always talk about in psoriasis is the itch that patients do experience from their psoriasis and the topical roflumilast was shown to reduce itch very quickly with patients and have a lasting effect. Dealing not only with the visible plaques, but also improving the symptoms. With symptoms such as itch, we can improve again the quality of life of the patient.

Roflumilast cream adds a much-needed element of simplicity for psoriasis patients and their dermatologists.  

The Value of Roflumilast Cream for Plaque Psoriasis 

Raj Chovatiya, MD, PhD, and assistant professor of dermatology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois, discusses Bristol Myers Squibb's deucravacitinib, a new oral therapy for the treatment of psoriasis. He also discusses a select number of autoimmune disorders such as lupus, psoriatic arthritis and inflammatory bowel disease.

Hi there, my name is Dr. Raj Chovatiya, and I'm an assistant professor of dermatology and director of the Center for Eczema and Itch at the Northwestern University Feinberg School of Medicine. So, let's spend a couple of minutes today talking about what I think is one of the most exciting advancements that we've had this year in dermatology, and there have been a lot, deucravacitinib. So, deucravacitinib, what is it? It's a first-in-class selective oral inhibitor of tyrosine kinase 2, or TYK2, which you may have heard of. Now, TYK2 is a member of the larger Janus kinase family. So, it's a family that includes other proteins like JAK one, 2, and 3, and TYK2 is exciting because it's actually responsible for the signaling of a lot of important cytokines we think about in psoriasis, IL-23,IL-12, type-1 interferons, things that we've learned a lot more about over the past couple of decades. Now, deucravacitinib is particularly unique because it's an allosteric inhibitor, meaning that it actually binds to a regulatory domain of TYK2 and avoids broader inhibition of the active sites of other JAK proteins. The other exciting thing is in addition to psoriasis, which we'll talk about in just a second, there's multiple immune-mediated diseases in which deucravacitinib is being studied. So, psoriatic arthritis, lupus, and inflammatory bowel disease to name a few. Now, when you think about psoriasis, a condition that affects millions, we know there's a huge comorbid health burden, really a lot of chronic need for this condition, and in particular, not many options available for targeted directed oral therapy. So, the POETYK phase 3 trial program, which studied deucravacitinib compared to placebo and currently the other targeted oral therapy on the market, apremilast for psoriasis, found that the majority of patients after 16 weeks treated with deucravacitinib achieved that PASI 75 benchmark we're looking for, almost at rates up to about 60%.

Additionally, the majority of people got to the point of being clear, almost clear on that PGA scale that we talk about, greater than 50%. And these responses even continued to increase when we looked at week 24 and beyond. A lot of other cool endpoints were met, including the Psoriasis Symptoms and Signs Diary and the Dermatology Life Quality Index, and what I think is an exciting bit of information: we always have one-year data to talk about, we now have 2-year data to talk about. It looks like the efficacy is really maintained throughout that entire time course. Now, the other question that a lot of folks have is adverse events. What does that look like? The good news is this agent that's achieving biologic-like efficacy in an oral form, mild to moderate severity, the most common things were sort of some of the common things we see in a lot of trials. And these are pharyngitis, upper respiratory tract infection and headache. And the good news is across all the phase 3 trials, things that we think about with a lot of other JAK inhibitors include malignancy, major adverse cardiovascular events, venous thromboembolic events, serious infections, and these are all generally low and consistent across active treatment groups. To me, a really big, exciting advancement in the field and I really can't wait to see patients have more options when it comes to control of their moderate to severe psoriasis.

Deucravacitinib offers new hope for those with moderate-to-severe plaque psoriasis. 

Emerging Therapies Plaque Psoriasis

Latest News